Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | FADS1 | O60427 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950170 | 0.89 | HTR6 (0.45) | HTR6FADS1MDM2TP53LDHA | |
| SCHEMBL27631232 | 0.89 | HTR6 (0.47) | HTR6FADS1MDM2TP53LDHA | |
| SCHEMBL6337525 | 0.83 | HTR6 (0.45) | HTR6FADS1MDM2LDHAGRM2 | |
| SCHEMBL20780486 | 0.82 | HTR2B (0.47) | HTR6FADS1HTR2B | |
| SCHEMBL20794011 | 0.82 | HTR2B (0.47) | HTR6FADS1HTR2B | |
| SCHEMBL13837966 | 0.82 | HTR2B (0.47) | HTR6FADS1HTR2B | |
| SCHEMBL15928300 | 0.81 | HTR6 (0.52) | HTR6FADS1MDM2TP53LDHA | |
| SCHEMBL9641472 | 0.81 | MDM2 (0.52) | HTR6FADS1MDM2TP53HTR2B | |
| SCHEMBL9063620 | 0.80 | F11 (0.41) | HTR6FADS1MDM2LDHAGRM2 | |
| SCHEMBL9063617 | 0.80 | F11 (0.41) | HTR6FADS1MDM2LDHAGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2020-07-16 | — | — | US | disclosed |
| WO-2019043018-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | HTR6 3502/4885FADS1 1182/4885MDM2 4280/4885 |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | HTR6 1158/4885FADS1 318/4885MDM2 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.